Yasuo Miyoshi

15PUBLICATIONS
37CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMechanobiologyGenome structure and regulation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jan 31, 2026
Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective study.

Yuri Takamatsu, Yoshiya Horimoto, Yasuo Miyoshi

|Jan 15, 2026
Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis.

Masato Takahashi, Hirofumi Mukai, Toshimi Takano

|Dec 17, 2025
KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy.

Hope S Rugo, David W Cescon, Mark E Robson

|Jun 18, 2025
An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia.

Masayuki Nagahashi, Miki Komatsu, Sayaka Urano

|Feb 20, 2025
Development and internal validation of a predictive model of overall and progression-free survival in eribulin-treated patients with breast cancer based on baseline peripheral blood parameters.

Keiko Natori, Masataka Igeta, Takashi Morimoto

|Mar 03, 2024
Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.

Reiko Fukui, Takahiro Watanabe, Koji Morimoto

Pageof 3

Frequent Collaborators

1 joint publications

Jun Takeuchi

1 joint publications

Masayuki Nagahashi

1 joint publications

Masayuki Nagahashi

1 joint publications

Miki Komatsu